Table 5.

Most frequent adverse events observed during the study

Adverse event	No. (%) of subjects having adverse event by group
	Secukinumab (n = 25)	Control (n = 25)	Total (n = 50)
Headache	6 (24.0)	2 (8.0)	8 (16.0)
Injection site pain	3 (12.0)	4 (16.0)	7 (14.0)
Oropharyngeal pain	1 (4.0)	2 (8.0)	3 (6.0)
Urinary tract infection	3 (12.0)	0 (0.0)	3 (6.0)
Nasopharyngitis	2 (8.0)	0 (0.0)	2 (4.0)
Tonsillitis	2 (8.0)	0 (0.0)	2 (4.0)
Toothache	1 (4.0)	1 (4.0)	2 (4.0)
Diarrhea	1 (4.0)	0 (0.0)	1 (2.0)
Fatigue	1 (4.0)	0 (0.0)	1 (2.0)
Oral herpes	1 (4.0)	0 (0.0)	1 (2.0)
Procedural pain	1 (4.0)	0 (0.0)	1 (2.0)
Pyrexia	0 (0.0)	1 (4.0)	1 (2.0)
Tracheitis	1 (4.0)	0 (0.0)	1 (2.0)
Vomiting	0 (0.0)	1 (4.0)	1 (2.0)